Eric M Gifford
Overview
Explore the profile of Eric M Gifford including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
178
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sheridan R, Wang W, Liaw A, Ma J, Gifford E
J Chem Inf Model
. 2016 Dec;
56(12):2353-2360.
PMID: 27958738
In the pharmaceutical industry it is common to generate many QSAR models from training sets containing a large number of molecules and a large number of descriptors. The best QSAR...
2.
Wild D, Ding Y, Sheth A, Harland L, Gifford E, Lajiness M
Drug Discov Today
. 2012 Jan;
17(9-10):469-74.
PMID: 22222943
Systems chemical biology, the integration of chemistry, biology and computation to generate understanding about the way small molecules affect biological systems as a whole, as well as related fields such...
3.
Chen B, McConnell K, Wale N, Wild D, Gifford E
Bioinformatics
. 2011 Sep;
27(21):3044-9.
PMID: 21903625
Motivation: Networks to predict protein pharmacology can be created using ligand similarity or using known bioassay response profiles of ligands. Recent publications indicate that similarity methods can be highly accurate,...
4.
Gupta R, Gifford E, Liston T, Waller C, Hohman M, Bunin B, et al.
Drug Metab Dispos
. 2010 Aug;
38(11):2083-90.
PMID: 20693417
Ligand-based computational models could be more readily shared between researchers and organizations if they were generated with open source molecular descriptors [e.g., chemistry development kit (CDK)] and modeling algorithms, because...
5.
Chang C, Duignan D, Johnson K, Lee P, Cowan G, Gifford E, et al.
J Pharm Sci
. 2009 Jan;
98(8):2857-67.
PMID: 19116953
As the cost of discovering and developing new pharmaceutically relevant compounds continues to rise, it is increasingly important to select the right molecules to prosecute very early in drug discovery....
6.
Arimoto R, Prasad M, Gifford E
J Biomol Screen
. 2005 Apr;
10(3):197-205.
PMID: 15809315
Computational models of cytochrome P450 3A4 inhibition were developed based on high-throughput screening data for 4470 proprietary compounds. Multiple models differentiating inhibitors (IC(50) <3 microM) and noninhibitors were generated using...